A Johnson & Johnson cancer treatment that can spare certain bladder cancer patients from the radical step of surgical removal of the organ now has FDA approval. J&J’s drug/device combination product, Inlexzo, came from the 2019 acquisition of Taris Biomedical.
If we truly believe in treating the whole patient, we must recognize that survival is not the only measure of success. Preserving a woman’s sense of self, her dignity, her identity, her autonomy is just as essential.
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
A growing body of evidence shows that structured lifestyle interventions such as physical activity, nutrition, and stress management aren’t just helpful; they also reduce cancer recurrence, improve quality of life, lower mortality, and even decrease healthcare costs.
Although the healthcare industry has a long way to go before PGx testing for DPYD and other genes becomes widespread, it's encouraging that regulatory bodies and professional organizations are making recommendations and raising awareness among healthcare providers.
Breast cancer survivor Kate Dilligan is the CEO of Cooler Heads, a company that sells a portable and self-administered scalp cooling device. The system helps chemotherapy patients retain their hair, and therefore their self-esteem and privacy.
A Fennec Pharmaceuticals drug that prevents hearing loss in children receiving cancer treatment is now approved. The regulatory decision comes more than two years later than expected, but the company now claims its drug, Pedmark, is the first and only FDA-approved therapy for reducing the risk of chemotherapy-induced hearing loss in pediatric cancer patients.
Alan Murray on improving access for medical transportation.
San Francisco-based Blumio and Saint Paul, Minnesota-based NxGenPort tied for the top prize in the Remote Patient Monitoring and Smart Devices track of INVEST Pitch Perfect, the startup competition integral to MedCity News' INVEST conference. Here is an in-depth look at each company.
BeyondSpring Pharmaceuticals’ corporate reorganization comes about six weeks after the FDA rejected the biotech’s drug for a complication experienced by cancer patients. The company still plans to develop the drug for that application and others, but it added that layoffs are needed to reduce expenses.
BeyondSpring Pharmaceuticals said the FDA wants another clinical trial to demonstrate patient benefit for its drug, a small molecule developed to treat a dangerous and life-threatening complication of chemotherapy. Shares of the biotech plunged more than 60% after the FDA’s complete response letter was announced.
Athenex’s bid to offer an oral version of an intravenous chemotherapy has stalled after the FDA rejected the drug. Among the remedies proposed by the regulator is another Phase 3 study.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
The drug offers greater convenience and efficacy than the old chemotherapy combination, but its high cost and first impressions among doctors may explain why Jazz had to lower its sales guidance.
The study can assure clinicians that Sandoz's Zarxio works just as well in febrile neutropenia as originator Amgen's Neupogen, author says in interview.
The American Society of Clinical Oncology is recommending that all patients age 65 and older receive a geriatric assessment when considering or undergoing chemotherapy.
While it's hard to get excited about a modified chemotherapy drug in an era of personalized medicine, checkpoint inhibitors, and CAR-T immunotherapies, Modra Pharmaceuticals' modified taxane drugs could make a sizeable impact in the field.
Symberix just raised $500,000 in SBIR grants to build out its microbiome-based drugs.